Sumitomo Mitsui Trust Group
NRIX icon

Sumitomo Mitsui Trust Group’s Nurix Therapeutics NRIX Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.9M Sell
983,462
-197,684
-17% -$3.37M 0.01% 607
2026
Q1 		$18.3M Sell
1,181,146
-109,408
-8% -$1.81M 0.01% 627
2025
Q4 		$24.5M Sell
1,290,554
-266,925
-17% -$3.83M 0.01% 615
2025
Q3 		$14.4M Buy
1,557,479
+165,841
+12% +$1.72M 0.01% 660
2025
Q2 		$15.9M Buy
1,391,638
+635,668
+84% +$6.87M 0.01% 644
2025
Q1 		$8.98M Sell
755,970
-33,252
-4% -$556K 0.01% 698
2024
Q4 		$14.9M Buy
789,222
+235,971
+43% +$5.41M 0.01% 679
2024
Q3 		$12.4M Buy
+553,251
New +$12.5M 0.01% 690

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sumitomo Mitsui Trust Group's NRIX Position: Q2 2026 in Review

Sumitomo Mitsui Trust Group reduced its Nurix Therapeutics (NRIX) stake by 17% in Q2 2026, selling an estimated $3.37M and leaving 983,462 shares worth $23.9M. The position accounts for 0.01% of the portfolio, ranked #607.

Sumitomo Mitsui Trust Group first reported a position in NRIX in Q3 2024 and has held it in 8 quarters since. The position peaked at $24.5M in Q4 2025. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Sumitomo Mitsui Trust Group held 983,462 shares of Nurix Therapeutics worth $23.9M as of Q2 2026.
  • Sumitomo Mitsui Trust Group sold 197,684 Nurix Therapeutics shares in Q2 2026, an estimated $3.37M.
  • Nurix Therapeutics made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q2 2026, its #607 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sumitomo Mitsui Trust Group's Nurix Therapeutics position peaked at $24.5M in Q4 2025.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q2 2026, filed 30 Jul 2026.